Is India Quietly Becoming a Favourable Hub for Clinical Trials?
DOI:
https://doi.org/10.55489/njcm.140920233201Keywords:
Clinical trial, India, Hub, EthicsAbstract
In recent years, India has become a go-to destination hub for clinical trials. The manpower, labour, patient recruitment, and medical infrastructure are cost-effective. India has a growing number of world-class research facilities and hospitals well equipped with advanced medical technology, which is essential for conducting high-quality clinical trials.
References
De A. Robust regulations, skilled professionals, Diverse pa-tient pool: Why India is becoming hub for drug trials. Available from https://news.abplive.com/india-at-2047/why-india-is-becoming-one-of. Last assessed on 19.05.2023.
Why India a favourite hub for clinical trials. Available from https://crbtech.in/india-favourite-hub-clinical-trials. Last assessed on 19.05.2023.
India an attractive hub for clinical research. Available from https://www.veedacr.com/india-an-attractive-hub-for-clinical-research. Last assessed on 19.05.2023.
Das NK, Patil R, Prasanna S, Das P, Mukhida S. Drones for Med-ical Supply During Disaster: A Game Changer in "Health for All" Policy. Health Services Insights. 2023;16. Doi: https://doi.org/10.1177/11786329231160013 PMid:36896146 PMCid:PMC9989367
Aksa. Can India serve as a hub for clinical trials? Despite the optimism of the drug industry, it should not recreate prior errors. Available from ttps://www.inventiva.co.in/trends/can-india-serve-as-a-hub-for-clinical-trials. Last assessed on 19.05.2023.
Thacker T. India emerging as a top destination for clinical tri-als, says report. Available from https://economictimes.india times.com/industry/healthcare//biotech/… Last assessed on 17.7.2023.
Hegde R. Why India is most preferred Clinical trial destina-tion. Available from www. biospectrumasia.com/article/pdf/ 22674. Last assessed on 17.7.2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Deepali Desai, Nikunja Kumar Das, Sahjid Mukhida, Radhika Paranjpe
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.